Future Directions in Pulmonary Arterial Hypertension: Novel Treatment Pathways, Evolving Treatment Paradigms, Addressing Differences in SDoH
Despite a multitude of treatment options, PAH continues to have a poor prognosis. Diagnostic delays, racial and ethnic disparities, and social determinants of health can all be contributing factors. This program will discuss ways to mitigate those factors, as well as explore screening tools and novel treatments.
This series is provided by Global Education Group and Iridium Continuing Education.